Wall Street analysts expect XBiotech Inc (NASDAQ:XBIT) to post ($0.15) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for XBiotech’s earnings. XBiotech posted earnings of ($0.16) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 6.3%. The firm is scheduled to issue its next earnings report on Thursday, August 8th.
According to Zacks, analysts expect that XBiotech will report full year earnings of ($0.61) per share for the current fiscal year. For the next financial year, analysts expect that the firm will post earnings of ($0.85) per share. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover XBiotech.
XBiotech (NASDAQ:XBIT) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter.
XBIT has been the topic of a number of analyst reports. BidaskClub cut XBiotech from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 14th. Piper Jaffray Companies assumed coverage on XBiotech in a report on Friday, June 14th. They issued an “overweight” rating and a $13.00 price objective on the stock.
In other news, major shareholder Fondation Rennes acquired 1,200,000 shares of the stock in a transaction that occurred on Tuesday, June 4th. The shares were bought at an average cost of $8.25 per share, for a total transaction of $9,900,000.00. Following the acquisition, the insider now owns 5,110,282 shares in the company, valued at approximately $42,159,826.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 33.40% of the company’s stock.
A number of hedge funds have recently bought and sold shares of XBIT. Vanguard Group Inc. lifted its stake in XBiotech by 5.5% in the 3rd quarter. Vanguard Group Inc. now owns 834,523 shares of the biopharmaceutical company’s stock worth $2,654,000 after purchasing an additional 43,648 shares in the last quarter. Tibra Equities Europe Ltd purchased a new position in XBiotech in the 1st quarter worth approximately $750,000. Birchview Capital LP purchased a new position in XBiotech in the 1st quarter worth approximately $110,000. Finally, Marshall Wace LLP purchased a new position in XBiotech in the 1st quarter worth approximately $682,000. Institutional investors own 7.05% of the company’s stock.
Shares of NASDAQ:XBIT traded up $0.10 during trading on Friday, reaching $7.39. 5,715 shares of the company’s stock traded hands, compared to its average volume of 242,893. XBiotech has a fifty-two week low of $2.13 and a fifty-two week high of $11.74. The stock has a market cap of $263.60 million, a price-to-earnings ratio of -12.63 and a beta of 0.47. The stock has a 50-day simple moving average of $8.21.
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Recommended Story: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.